Margaret M. Redfield

TL;DR: Weight loss, fluid loss, and NT-proBNP reduction at 72 hours are poorly correlated with dyspnea relief, but favorable improvements in each of the 3 markers were associated with improved clinical outcomes at 60 days, suggesting the need for ongoing research to understand the relationships among symptom relief, congestion, and outcomes in patients with acute decompensated heart failure.

TL;DR: A U-shaped curve for short-term prognosis according to BMI is seen in AHF, and patients with normal weight showed the highest risk of 60-day composite outcome, followed by patients who were severely obese.

TL;DR: By any metric, HF imposes a major public health and financial burden on society and the lack of new disease-modifying pharmacological therapy for HF over the past 2 decades further amplifies these concerns.

TL;DR: In this article, a meta-analysis of 16 studies characterizing the association between renal impairment and mortality in patients with acute decompensated heart failure (ADHF) indicated that 1-year mortality increased incrementally across the range of renal function with a 7% increase in risk for every 10 mL/min decrease in GFR.

TL;DR: The WS-VAS better reflects symptom improvement across the spectrum of AHF phenotypes and was associated with available decongestion markers (change in N-terminal pro-B-type natriuretic peptide, weight or cumulative 72-hour urine volume).